FORMULATION ARTICLES
-
Validation Of A RIG-I–Based Functional Assay For Quantitative Detection Of Double-Stranded RNA Impurities In mRNA Drug Substance
A validated RIG-I assay adds a biology-informed layer to dsRNA testing by quantifying immunogenic impurities in IVT-derived mRNA therapeutics for deeper functional insight.
-
Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease
Suppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.
-
Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset
In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.
-
Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics
Designing repeat-dose RNA means engineering around immune recognition — optimizing payloads, purity, and delivery early to sustain efficacy, tolerability, and durability across multiple administrations.
-
A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis
Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.
-
A New Approach To RNA Synthesis And Purification: Rethinking A Persistent Bottleneck
Photocleavable supports enable light-triggered RNA release, reducing reliance on chromatography and streamlining synthesis, scalability, and purity for complex RNA therapeutics.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Explore how to use and amplify pDNA from the development of recombinant proteins and viral vectors to advanced bio-therapeutics such as mRNA vaccines.
-
Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.
-
Polyethylene glycol and similar variants have driven innovative research for therapies. However, the continued use of PEG poses significant drawbacks.
-
The path to regulatory approval for LNPs demands carefully considered strategies. By adopting proactive and strategic approaches, developers can overcome regulatory hurdles on the path to approval.
-
Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.
-
A comparative study examines how two mixing technologies, microfluidic and turbulent jet, influence the attributes of lipid nanoparticles and their suitability for different stages of drug development.
-
Single-use technology is vital for ensuring the quality and expedited market entry of genomic medicines. Learn how LNP technology is paving the way for a new era of personalized, precise medicine.